Brii Bio signs licensing deal with Joincare Group for antibiotic BRII-693 in China

4 July 2025

Chinese biotech Brii Biosciences (HKEX: 2137) has licensed its experimental antibiotic BRII-693 to domestic pharma business Joincare Group for development and commercialization in China, as part of a technology transfer and exclusive licensing agreement announced on Wednesday.

Under the deal, Joincare will lead on development, regulatory filings, and commercialization of the asset. In return, Brii Bio receives an undisclosed upfront payment, with further payments tied to development and sales milestones. The company is also set to receive tiered royalties on net sales.

BRII-693 is a synthetic lipopeptide in development to treat patients hospitalized with serious gram-negative bacterial infections that are resistant to multiple antibiotics. The drug is designed to tackle infections caused by highly resistant pathogens.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK